178 related articles for article (PubMed ID: 34873918)
1. Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature.
Gemelli M; Carbone M; Abbate MI; Mancin M; Zucchini N; Colonese F; Invernizzi P; Bidoli P; Cortinovis D
Immunotherapy; 2022 Mar; 14(4):175-181. PubMed ID: 34873918
[TBL] [Abstract][Full Text] [Related]
2. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced Liver Injury Considered Steroid-resistant and Histologically Diagnosed with Vanishing Bile Duct Syndrome.
Shionoya K; Kobayashi M; Kako M; Masuda S; Makazu M; Koizumi K
Intern Med; 2024 Jun; 63(12):1719-1723. PubMed ID: 37952956
[TBL] [Abstract][Full Text] [Related]
4. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
Zhong YY; McLean L; Buckle A; Siva S; Tran B
Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
[TBL] [Abstract][Full Text] [Related]
5. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
6. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
7. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
8. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.
Bonkovsky HL; Kleiner DE; Gu J; Odin JA; Russo MW; Navarro VM; Fontana RJ; Ghabril MS; Barnhart H; Hoofnagle JH;
Hepatology; 2017 Apr; 65(4):1267-1277. PubMed ID: 27981596
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
12. Improvement of vanishing bile duct syndrome with hyperlipidemia.
Yamauchi R; Takata K; Fukunaga A; Tanaka T; Yokoyama K; Shakado S; Nabeshima K; Yoshimitsu K; Hirai F
Clin J Gastroenterol; 2022 Aug; 15(4):784-790. PubMed ID: 35802301
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.
Rota Scalabrini D; Caravelli D; Carnevale Schianca F; D'Ambrosio L; Tolomeo F; Boccone P; Manca A; De Rosa G; Nuzzo A; Aglietta M; Grignani G
BMC Res Notes; 2014 Aug; 7():529. PubMed ID: 25125318
[TBL] [Abstract][Full Text] [Related]
14. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
[TBL] [Abstract][Full Text] [Related]
15. Lamotrigine-induced vanishing bile duct syndrome in a child.
Bhayana H; Appasani S; Thapa BR; Das A; Singh K
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):e147-8. PubMed ID: 22008955
[No Abstract] [Full Text] [Related]
16. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
17. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
[TBL] [Abstract][Full Text] [Related]
18. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
19. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
20. Vanishing bile duct syndrome in a HIV patient on HAART therapy.
Gnanaraj J; Fiedler P; Virata M
BMJ Case Rep; 2011 Sep; 2011():. PubMed ID: 22679317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
